A number of other equities research analysts have also weighed in on ABCO. Oppenheimer Holdings Inc. set a $45.00 target price on shares of The Advisory Board and gave the stock a buy rating in a report on Thursday, July 28th. Cantor Fitzgerald restated a hold rating on shares of The Advisory Board in a report on Friday, August 19th. Credit Suisse Group AG restated a buy rating and issued a $50.00 target price on shares of The Advisory Board in a report on Friday, September 16th. Craig Hallum upgraded shares of The Advisory Board from a hold rating to a buy rating and set a $47.00 target price on the stock in a report on Thursday, July 28th. Finally, Zacks Investment Research lowered shares of The Advisory Board from a strong-buy rating to a hold rating in a research note on Tuesday, July 12th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $44.07.
Shares of The Advisory Board (NASDAQ:ABCO) opened at 43.50 on Wednesday. The company has a 50 day moving average price of $42.77 and a 200 day moving average price of $36.66. The company’s market capitalization is $1.75 billion. The Advisory Board has a 52 week low of $18.87 and a 52 week high of $54.84.
The Advisory Board (NASDAQ:ABCO) last posted its earnings results on Wednesday, July 27th. The company reported $0.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.13. The Advisory Board had a negative net margin of 10.21% and a positive return on equity of 11.59%. The company had revenue of $198.40 million for the quarter, compared to analyst estimates of $196.49 million. During the same quarter in the prior year, the business posted $0.40 EPS. The firm’s revenue was up 7.4% compared to the same quarter last year. On average, equities research analysts expect that The Advisory Board will post $1.86 earnings per share for the current year.
In related news, Director Peter J. Grua sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $41.44, for a total value of $103,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Evan R. Farber sold 2,924 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $40.95, for a total transaction of $119,737.80. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABCO. Bank of Montreal Can acquired a new position in The Advisory Board during the second quarter valued at approximately $8,706,000. Fox Run Management L.L.C. acquired a new position in The Advisory Board during the second quarter valued at approximately $297,000. Royal Bank of Canada increased its position in The Advisory Board by 6.0% in the first quarter. Royal Bank of Canada now owns 1,252,911 shares of the company’s stock valued at $40,406,000 after buying an additional 70,769 shares during the period. A.R.T. Advisors LLC increased its position in The Advisory Board by 615.3% in the first quarter. A.R.T. Advisors LLC now owns 42,781 shares of the company’s stock valued at $1,379,000 after buying an additional 36,800 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in The Advisory Board during the first quarter valued at approximately $6,165,000.
The Advisory Board Company Profile
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.
Receive News & Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related companies with MarketBeat.com's FREE daily email newsletter.